Calcification of human vascular smooth muscle cells: associations with osteoprotegerin expression and acceleration by high-dose insulin by Olesen, Ping et al.
Calcification of human vascular smooth muscle cells: associations with
osteoprotegerin expression and acceleration by high-dose insulin
Ping Olesen,1 Kirsten Nguyen,1 Lise Wogensen,1 Thomas Ledet,1 and Lars Melholt Rasmussen1,2
1Research Laboratory for Biochemical Pathology, Institute of Clinical Medicine; and
2Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark
Submitted 10 January 2006; accepted in final form 10 October 2006
Olesen P, Nguyen K, Wogensen L, Ledet T, Rasmussen LM.
Calcification of human vascular smooth muscle cells: associations
with osteoprotegerin expression and acceleration by high-dose insulin.
Am J Physiol Heart Circ Physiol 292: H1058–H1064, 2007. First
published October 20, 2006; doi:10.1152/ajpheart.00047.2006.—Ar-
terial medial calcifications occur often in diabetic individuals as part
of the diabetic macroangiopathy. The pathogenesis is unknown, but
the presence of calcifications predicts risk of cardiovascular events.
We examined the effects of insulin on calcifying smooth muscle cells
in vitro and measured the expression of the bone-related molecule
osteoprotegerin (OPG). Human vascular smooth muscle cells
(VSMCs) were grown from aorta from kidney donors. Induction of
calcification was performed with -glycerophosphate. The influence
of insulin (200 U/ml or 1,000 U/ml) on calcification was judged by
measuring calcium content in the cell layer and by von Kossa staining.
OPG was measured in the medium by ELISA. Histochemistry was
used for determination of alkaline phosphatase (ALP). Bone sialopro-
tein (BSP) and OPG mRNA expressions were done by RT-PCR.
-Glycerophosphate was able to induce calcification in human smooth
muscle cells from a series of donors after variable time in culture.
Decreased OPG amounts were observed from the cells during the
accelerated calcification phase. High dose of insulin (1,000 U/ml)
accelerated the calcification, whereas lower concentrations (200 U/
ml) did not. Calcified cells expressed ALP and BSP activity in high
levels. In conclusion, high concentration of insulin enhances in
vitro-induced calcification in VSMCs. Altered OPG levels during the
calcification raise the possibility that OPG may have a potent function
in regulating the calcification process or it may represent a conse-
quence of mineralization. Effects of insulin and modulations by OPG
on the calcification process in arterial cells may play a role in the
development of calcifications as part of the diabetic macroangiopathy.
atherosclerosis; macroangiopathy; arterial
DIABETIC PATIENTS harbor linear calcifications in the arterial
tunica media with a high prevalence (12, 33). These calcifica-
tions are considered to be an element of the diabetic macroan-
giopathy, a pathological entity, which includes a series of
diffuse nonatherosclerotic arterial changes, particularly related
to the extracellular matrix (17, 18). The degree of medial
calcifications is associated with the glucose tolerance and the
duration of diabetes (12). Interestingly, medial calcifications in
the femoral artery are strong, independent predictors of car-
diovascular mortality in diabetes (5, 13), putatively because the
calcifications mark the presence of generalized diabetic mac-
roangiopathy, which may provide a fertile soil for atherogen-
esis (2). The mechanisms leading to calcium deposits in the
arterial media in diabetes are, however, unknown.
Recent data suggest that arterial calcifications occur as the
result of an active, regulated process. This idea is based partly
on findings of high expression of bone-related macromole-
cules, such as alkaline phosphatase (ALP), bone sialoprotein
(BSP), and bone Gla protein in calcified areas of the arterial
wall (3, 8, 23, 30). Moreover, in vitro studies of vascular
smooth muscle cells have demonstrated that these cells adjust
expression of both Cbfa1 (an osteoblast differentiation-induc-
ing transcription factor) and several bone-related molecules,
like BSP, when calcification is induced (7, 22). Furthermore,
direct evidence comes from gene knockout experiments of
matrix-Gla protein and osteopontin-lacking mice, which de-
velop extensive vascular calcification. Also, osteoprotegerin
(OPG)-deficient mice develop arterial calcifications, suggest-
ing that this osteoclast inhibitor, in addition, functions as an
inhibitor of vascular calcification (1). The role of OPG is,
nevertheless, unclear, since the OPG knockout animals develop
severe osteoporosis, raising the suggestion that vascular alter-
ations may be caused by systemic effects of extreme osteoclast
overfunction. At present, no information is, however, available
concerning the putative relation between OPG- and in vitro-
induced calcification in vascular cells. Recent data suggest that
OPG may play a special role in arterial disease in diabetes,
since increased levels are found in aortic tunica media from
diabetic patients (14). Altered arterial OPG concentrations and
medial calcifications may thus hypothetically be associated and
could be markers of diffuse arterial alterations in diabetes, i.e.,
diabetic macroangiopathy, reflecting effects of metabolic and
hormonal factors on the vasculature.
Compensatory hyperinsulinemia prevails in Type 2 diabetes
as a result of insulin resistance, especially in skeletal muscles.
Since epidemiological studies have shown an independent
relation between cardiovascular diseases and hyperinsulinemia
(6, 28), insulin has been suggested as a mediator of vascular
alterations in diabetes. Moreover, animal models of hyperin-
sulinism, as, for example, the Zucker rat, show diffuse arterial
changes of the same diffuse type as seen in patients with
diabetes (17, 18), as recently shown by Sista et al. (26). These
changes may at least partly reflect direct insulin effects, since
the vasculature is an insulin target organ and both endothelial
and smooth muscle cells express insulin receptors. In vitro,
insulin influences mitogenesis and chemotaxis in vascular
smooth muscle cells (15, 19, 29), although new evidence
questions these effects in human vascular cells (9, 27). Inter-
estingly, insulin decreases the production of hyaluronic acid
(4) and OPG (14) in short-term experiments with human
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vascular smooth muscle cells. The influence of insulin on the
calcification-related molecule OPG suggests that an interplay
between these molecules may influence the occurrence of
medial calcifications in diabetes; however, no data concerning
this idea are available.
The objective of the present study was to study the possible
relation between in vitro-induced calcification of smooth mus-
cle cells and OPG. Moreover, we aimed to investigate putative
effects of insulin on the calcification process.
MATERIALS AND METHODS
Human vascular smooth muscle cell culture. Human vascular
smooth muscle cells were grown from explants of normal aortic
tissues, obtained from excess donor vasculature at kidney transplan-
tations. The cells were cultivated as previously reported (4). For
experiments, cells were grown in DMEM (Sigma D5523) containing
10% FBS and were used between passages 3 and 6. The quantitative
part of this study included experiments with cells derived from eight
different aortic donors. The local ethical committee approved the
growing of cells.
Induction of calcification of human vascular smooth muscle cells.
Single-cell suspensions (4  104 cells/well) were placed in culture
plates in DMEM containing 10% FBS (growth medium). After ad-
herence, cells were switched to calcification medium consisting of the
growth medium supplemented with 8 mM -glycerophosphate. Me-
dium was replaced twice a week. For time course experiments, the
first day of culture in the calcification medium was defined as day
0. For calcium and protein measurements, 6  24-well plates were
used for six time points. Each plate contained between four and six
wells for each treatment group (calcification medium, calcification
medium in presence of insulin and control growth medium). For RNA
isolation cells were seeded in six-well plates.
Quantitation of calcium and protein content. The cultures were
decalcified with 0.6 N HCl for 24 h. The calcium content of the HCl
supernatant was determined by the o-cresolphthalein Complexone
method (calcium kit 587-A, Sigma). After decalcification, the cells
were washed with PBS and solubilized with 0.1 N NaOH-0.1% SDS.
Total protein content was measured using MicroBCA Protein Assay
Reagent Kit (Pierce) with bovine serum albumin as standard. The
calcium content of the cell layer was normalized to total protein
content.
Cytochemical staining for mineral deposit and ALP. Von Kossa
staining was used to confirm the presence of mineral deposits. Cell
cultures were stained with 5% silver nitrate for 30 min. The calcium
phosphate salts were demonstrated as black stain. Activity of ALP
was demonstrated in cultured cells after being washed with PBS and
incubated with substrate consisting of 2 mg/ml naphthol AS-BI
phosphate sodium salt (Sigma N-2250) and 1 mg/ml fast red violet LB
salt (Sigma F-1625) in 0.1 M Tris buffer (pH 8.2) at 37°C for 30 min
and washed with PBS, followed by fixation in 4% formaldehyde
buffer for 10 min. Cells were washed in distilled water, counterstained
with Mayer hematoxylin for 2 min, and finally washed in water.
OPG measurements. During the calcification process, conditional
medium was collected and stored at 20°C until analysis. The
concentration of OPG in the conditional medium was determined by
a commercially available sandwich ELISA (catalog no. DY805, R&D
Systems, Minneapolis, MN), as previously described (14). The assay
employs mouse anti-human OPG as capture antibody and a biotinyl-
ated goat anti-human OPG for detection, which is visualized by
horseradish peroxidase-conjugated streptavidin.
RNA isolation and quantitative RT-PCR. Total RNA was extracted
from cells grown in six-well culture dishes by using 500 l of TRIzol
(Invitrogen) according to the instructions from the manufacturer. The
Fig. 1. Calcium accumulates variably in the cell layer of -glycerophosphate
(8 mM)-treated vascular smooth muscle cells (VSMCs) from different donors.
Cells were treated with -glycerophosphate, after which the calcium content in
the cell layer was measured at the indicated time points. Results from four
donors with variable responses are shown: ‚, early rapid calcification; ,
abrupt calcification after longer time; , slow but continuous increase in
calcium content; E, almost no calcification, despite prolonged incubation. The
calcium content from non--glycerophosphate-treated control cells from each
donor never exceeded 10 g/mg protein (not shown). Results are mean values
from 4–6 cultures for each time point.
Fig. 2. Osteoprotegerin (OPG) secretion decreases in cal-
cifying human VSMCs. OPG amounts in the medium (A)
and calcium content in the cell layer (B) are shown for
different time points in cultures treated with -glycerophos-
phate (Cal) and normal growth medium without -glycer-
ophosphate (GM). *P  0.05 and **P  0.01 compared
with control cells. Data are shown as means  SD of 4
cultures from 1 donor.
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amount of isolated RNA was ensured by measuring the optical density
at 260 and 280 nm. Total RNA (1 g) was used with random
hexamers and murine Moloney leukemia virus-reverse transcriptase
(GIBCO-BRL) for reverse transcription in 30 l reaction mixture. The
quantitative RT-PCR procedure was performed as previously de-
scribed (14). Real-time PCR was performed in 25 l amplification
mixture containing 12.5 l SYBR Green Supermix (Bio-Rad), 2 l
cDNA from RT solution, and 10 pmol primer sets. The relative
standard curves were generated by using a sample cDNA with high
RNA content diluted 5- to 125-fold. PCR was performed with two
primer sets, specific for human BSP (5-TGG AAA TCG TTT TAA
ATG AGG ATA and 5-AAG CAA TCA CCA AAA TGA AGA CT),
OPG (5-GGA ACC CCA GAG CGA AAT AC and 5-CCT GAA
GAA TGC CTC AC), and -actin (5-GTC CAG ACG CAG GAT
GGC ATG and 5-CTA CAA TGA GCT GCG GTG GGC). Standards
and samples were run in duplicate. The efficiency of the PCR
amplifications for BSP, OPG, and -actin were 98%. Results are
expressed as the ratio of OPG mRNA units to -actin mRNA units.
Statistical analysis and assessment of results from multiple donors.
As mentioned in RESULTS, the rate of calcium accumulation differed
considerably between experiments (i.e., donors). To be able to com-
bine the results from different experiments for statistical evaluation,
we divided each experiment into two periods: a precalcification phase,
during which the average calcium concentration in the -glycerophos-
phate-treated control wells was below 20 g/mg protein, and a
calcifying phase, where the average calcium content in the -glycer-
ophosphate-treated control cultures was above 20 g/mg protein. An
average result from each treatment modality for each donor for each
calcification phase (when available) was calculated and used for
presentation.
All results are expressed as means  SD. Differences between
groups were tested by ANOVA and Student’s t-test (paired, whenever
relevant). A two-tailed P value 0.05 was considered significant.
RESULTS
In vitro calcification of human vascular smooth muscle cells.
The addition of -glycerophosphate to cultures of vascular
smooth muscle cells induced calcification, as judged by the
accumulation of calcium in the cell layer. However, the rate of
calcium deposit varied extensively between different experi-
ments, using different donors (4 examples are shown in Fig. 1).
Most experiments were characterized by an initial period of
varying length, with only slowly rising calcium levels, fol-
lowed by a second phase, with cellular calcium concentrations
above 20 g/mg protein. However, some cultures had a con-
tinuous slow course, and cells from a few donors did not
incorporate significant amounts of calcium, even after pro-
longed incubation periods with -glycerophosphate (Fig. 1).
Fig. 3. Insulin increases calcification in the cell layer of -glyc-
erophosphate-treated VSMCs. Cellular calcium content from
experiments with two donors is shown: an example of a late
calcifying culture with rather low calcium values (A) and an
early calcifying culture with higher calcium incorporation (B).
Cells were treated for the indicated time periods. GM, results
from control cells (normal growth medium); Cal, the addition
of -glycerophosphate; Cal 	 Ins 200 and Cal 	 Ins 1,000,
results from -glycerophosphate-treated cultures, which, in
addition, received 200 U/ml and 1,000 U/ml insulin, respec-
tively. *P  0.01 when compared with control cells. **P 
0.01 vs. -glycerophosphate-treated cells. Data represent
means  SD (n 
 4–6 cultures).
Table 1. Average calcium and protein content in the cell layer together with secreted amounts of osteoprotegerin in cultures
of human vascular smooth muscle cells from several donors treated with -glycerophosphate and insulin
Cellular Calcium,
g/mg protein
Cellular Protein,
g/well
Secreted Osteoprotegerin,
ng/g protein
Precalcification
GM 5.43.5 (n
8) 183.258.2 (n
8) 1.371.13 (n
8)
Cal 14.97.2 (n
8)* 179.260.3 (n
8) 1.380.94 (n
8)
Cal 	 Ins 200 15.82.9 (n
4) 194.780.1 (n
4)† 1.971.27 (n
4)
Cal 	 Ins 1,000 28.514.4 (n
7)† 207.767.3 (n
7)† 1.060.81 (n
6)
Calcification
GM 8.15.6 (n
8) 232.363.8 (n
8) 2.712.59 (n
7)
Cal 90.874.7 (n
8)* 235.771.6 (n
8)* 1.320.85 (n
7)†
Cal 	 Ins 200 145.077.3 (n
6) 240.185.7 (n
6) 1.120.84 (n
4)
Cal 	 Ins 1,000 208.0210.6 (n
5)† 238.927.1 (n
5)† 0.790.36 (n
4)†
Values are means  SD; n, number of individual artery donors available for paired t-test. GM, normal growth medium; Cal, cultures treated with 8 mM
-glycerophosphate; Cal 	 Ins, Cal with the addition of insulin (200 U/ml or 1,000 U/ml). Results are evaluated from a series of experiments: from each
donor a large collection of cultures was used and results were averaged (n 
 4–6 cultures) for each treatment group for each calcification phase (precalcification
and calcification) as described in MATERIALS AND METHODS. Precalcification is defined as cellular calcium 20 g/mg in the Cal group; calcification as cellular
calcium 20 g/mg in Cal group. *P  0.01 vs. GM; †P  0.05 vs. Cal. Paired t-test was used to judge differences between treatment groups.
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OPG secretion decreases in calcifying cultures. OPG was
measured in the medium of calcifying cultures, and a typical
example of results can be seen in Fig. 2. No difference in the
OPG levels was seen in the -glycerophosphate-containing
medium vs. control medium at stages where the cellular cal-
cium was low or only moderately increased. However, at a
later stage, when calcium levels (Fig. 2B) were high, there was
a large, significant decrease in the secretion of OPG (Fig. 2A).
These results could also be observed when results from several
donors were statistically evaluated, as seen in Table 1. In other
experiments, we determined the relation between OPG produc-
tion and different cell densities. It was found that the rate of
OPG synthesis is negatively associated with cell numbers.
Smooth muscle cells were seeded to a final density at 103, 104,
and 105 cells/ml, and OPG production expressed per cell (in
pg ml1 day1 cell1) was 9.78, 8.44 (P  0.01 compared
with 103 cells/ml), and 1.62 (P  0.01 compared with 103
cells/ml), respectively. Furthermore, the effects of different
concentrations of PO43 and -glycerophosphate on OPG in
smooth muscle cells were also compared, and no significant
differences were found after 1, 2, and 3 mM of PO43 and 4, 8,
and 12 mM of -glycerophosphate were added to the control
medium (PO43: 0.9 mM) for 24 h (data not shown).
Insulin accelerates vascular calcification. Results from ex-
periments with the addition of insulin to calcifying cells from
two different donors are shown in Fig. 3. Both in cells with
moderately elevated calcium levels and in cells that have
achieved higher calcium levels, it can be seen that cultures
treated with insulin incorporate more calcium than control
cells. The combined results from a large series of experiments
with cultures from different donors can be seen in Table 1. In
line with results in Fig. 3, Table 1 shows that the calcium
content in cultures treated with high doses of insulin (1,000
U/ml) was statistically significantly increased, whereas a
lower insulin dose showed only a trend toward augmented
levels in late calcification. The combined results also show
that, in the precalcification period, there was higher protein
content in insulin-treated cultures when compared with the
cultures without insulin (Table 1). No significant differences in
protein content were, however, seen when cultures at later
stages of calcification were considered (Table 1). In addition to
biochemical analysis, calcium deposits were also identified by
von Kossa staining, which supported the finding of increased
calcifications of cells treated with insulin (Fig. 4). A large
number of granular formations developed in cultures treated
with -glycerophosphate, and both size and amounts seemed to
be increased when insulin was present in the calcification
medium. No deposits were seen in cells cultured in the normal
growth medium (Fig. 4). We also found high ALP expression
in calcifying cultures (Fig. 4), whereas cultures without the
addition of -glycerophosphate had very low levels, as judged
by light microscopy. Similar to calcium deposits, increased
staining was present in the insulin-treated cultures. BSP
mRNA was measured by real-time PCR, and in calcifying
Fig. 4. Calcium deposits and alkaline phosphatase expression in insulin- and -glycerophosphate-treated human VSMCs. A–C: von Kossa staining. D–F:
cytochemical detection of alkaline phosphatase activity. A and D: cells treated with -glycerophosphate and 1,000 U/ml insulin. B and E: cells only treated
with -glycerophosphate. C and F: control cells. Cells were incubated for 36 days.
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cells, there was a significant increased BSP mRNA level versus
control cells. In the presence of insulin (1,000 U/ml), the
expression of BSP was strongly upregulated (Fig. 5).
As can be seen in Fig. 6 (and Table 1), insulin addition at
high concentrations led to a further decrease of the previously
mentioned downregulation of OPG synthesis induced by cal-
cification. However, insulin had no effects in cultures grown in
calcification medium in the precalcification phase (Table 1).
The effect of high-dose insulin was paralleled when OPG
mRNA amounts were considered (Fig. 7).
DISCUSSION
In the present investigation, we experienced that it is possi-
ble to induce calcification by -glycerophosphate treatment in
primary cultures of human vascular smooth muscle cells,
although we found that the rate and the extent of calcium
accumulation in the cell layer vary greatly between experi-
ments. Several different versions of in vitro models of vascular
calcifications have been reported (including -glycerophos-
phate treatment) (7, 16, 24), and it seems that different calci-
fication profiles may be achieved, although data on variation
are sparse, especially concerning human cells. Nevertheless,
one study agrees with the present finding, describing calcifi-
cation in cells from two human donors where calcification was
obtained after 1 and 3 wk, respectively (34). In contrast,
-glycerophosphate-induced calcification in bovine vascular
cells is seen with less variability, and it seems that bovine cells
calcify at a much quicker rate (24). In addition to differences
between species, it is clear that there is also a large difference
in calcification profile between different experimentally in-
duced calcification pathways. Cells harvested from these nod-
ules by collagenase treatment can calcify spontaneously (31) or
after induction with phosphate, and the process develops rather
quickly (7) (calcifying vascular cells), whereas induction with
-glycerophosphate develops with a more variable rate, puta-
tively relating to the expression level of ALP. The variability in
both systems using human cells probably reflects differences of
age, sex, and genetic constitution between donors. Moreover, it
is likely that factors related to the selection of cells in the initial
harvest of tissue may play a role (e.g., origin is intima/media,
etc.). In both models, it seems that calcium accumulation is
paralleled with an increase in ALP activity and BSP expres-
sion, as seen in the present study and as previously reported
Fig. 5. Expression of bone sialoprotein (BSP) mRNA in calcifying VSMCs is
enhanced by insulin. Cells were treated for the indicated time periods, RNA
was isolated, and BSP mRNA was analyzed. Data represent means  SD (n 

4 cultures). No difference in the amount of -actin was seen between the
different groups, when expressed per g total RNA. arb, Arbitrary. *P  0.05
when compared with control cells. **P  0.05 and ***P  0.01 when
compared with -glycerophosphate-treated cells (Cal).
Fig. 6. Insulin decreases OPG secretion parallel to calcium incorporation.
Cells were treated for 25 days, and OPG content in the medium (A) as well as
calcium content in the cell layer (B) was measured. *P  0.01 when compared
with control cells; **P  0.05 when compared with -glycerophosphate-
treated cells (Cal); ***P  0.01, result from -glycerophosphate-treated cells
with addition of 1000 U/ml insulin vs. -glycerophosphate-treated cells
without insulin. Data are represented as means  SD (n 
 4–6).
Fig. 7. Insulin decreases OPG mRNA in calcifying VSMCs. Cells were
incubated for 18 days, RNA was isolated, and OPG mRNA/-actin mRNA
was determined (A) together with cellular calcium content in parallel cultures
(B). Data are presented as means  SD (n 
 4 cultures). No differences in the
amount of -actin between the different groups were seen when expressed per
g total RNA. *P 0.01 when compared with control cells (GM); **P 0.05
vs. Cal; ***P  0.01 result from Cal 	 Ins 1,000 vs. Cal.
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(22, 24). The large variation provides an experimental chal-
lenge when trying to extract information about molecular
mechanisms from the calcification process. Nevertheless, our
results, combining data from several donors, show that vascu-
lar calcification is associated with altered OPG levels and that
insulin at high doses can accelerate the process.
OPG was first discovered as an osteoclast inhibitor in 1997
(25). Later observations suggested that the molecule also may
work as an inhibitor of vascular calcification, since approxi-
mately one-third of OPG knockout mice develop calcium
deposits in the arterial wall (1). This indication is in line with
the fact that OPG is present in the vasculature in mice (1) and
humans (14). OPG was, moreover, found to be overexpressed
in relation to calcified areas and also in certain places in
atherosclerotic tissue, as seen in immunohistochemical studies
(3, 30), whereas in biochemical measurements, we did not find
OPG amounts in altered amounts in atherosclerotic areas (14).
In the present study, we found a downregulation of OPG
amounts in the medium from cells during accelerated calcifi-
cation. Whether the increased calcification could be related to
the lack of calcification inhibition by OPG remains to be seen,
but the finding does, at least, clearly show that the amount of
OPG is strongly related to the calcification process in vitro.
The biological effect of OPG is mediated through its binding
and neutralization of either receptor activator of NF-B ligand
(RANKL) or TNF-related apoptosis-inducing ligand (TRAIL),
two members of the TNF- superfamily (32). Both molecules
have been found in vascular cells, and at least RANKL has
been suggested to be involved in vascular calcification (10, 20).
In this study, we attempted to measure TRAIL and RANKL in
conditioned media, but we were not able to find sufficient
amounts for immunological detection (data not shown). Down-
regulation of OPG during calcification could, nevertheless,
lead to altered activity of the two TNF-related molecules, but
further studies to elucidate this hypothesis are needed. Inter-
estingly, we did not observe differences in the expression of
OPG mRNA between calcifying and control cells at the time
where low OPG protein levels were seen in the cells. This may
indicate that the level of OPG is regulated differently, at both
the transcriptional, translational, and possibly also posttransla-
tional level by different stimuli. Increased degradation of the
molecule in calcifying cultures could, for example, be a pos-
sibility, whereas regulation by insulin is at the RNA level, as
we also previously observed (14).
In the present study, we observed that insulin at a high
concentration accelerates the calcification process in vitro. This
induction was related to overexpression of bone-related mole-
cules, i.e., ALP and BSP, and OPG downregulation. We found
a slight increase in cellular protein content of insulin-treated
cultures in the precalcification period (20 g calcium/mg
protein). It is noteworthy that the total cellular amount in the
cultures does not alter much throughout the experiments,
indicating that the experiments are carried out during a steady-
state period. The result could indicate that insulin may influ-
ence the balance between cell proliferation and apoptosis.
Recent studies, which did not observe any effects of insulin on
the proliferation or apoptosis of vascular smooth muscle cells
(27), seem, however, to indicate that other factors, i.e., effects
on the general protein metabolism, may be more important.
The effect of insulin on calcification may relate to its capacity
to alter synthesis of both hyaluronan (4), CD44 (21), and OPG
(14) in vascular smooth muscle cells. In line with these previ-
ous observations, we observed OPG downregulation by insulin
in the calcification period but did surprisingly not find effects
of insulin on OPG secretion in the precalcification period. This
is in contrast to our previous investigations of acute effects of
insulin (14). However, it is important to realize that the earlier
studies were performed under serum-free conditions and that
the present studies were performed over several weeks and in
the presence of serum. The observed effects of insulin on the
accumulation of calcium deposits are interesting, since vascu-
lar calcifications are observed with increased prevalence in
patients with Type 2 diabetes, a group of patients suffering
from hyperinsulinism. It should, however, be noted that we
only found the cellular effects of insulin at high concentrations.
In this context, it is also noteworthy that insulin can lower OPG
production in normal vascular smooth muscle cells in serum-
free conditions at much lower concentrations, as we previously
reported (14). This could indicate that the different effects of
insulin may follow dual signaling pathways, depending on
concentration.
Medial calcifications in diabetes are good predictors of
cardiovascular diseases in patients with Type 2 diabetes (5,
13), putatively because they mark the presence of other ele-
ments of the diabetic macroangiopathy of which some are
known to accelerate the atherogenic process (2). The calcifi-
cations are associated with the duration of diabetes and with
the magnitude of the glucose intolerance (11) and may relate to
matrix alterations and possible accumulation of bone-related
molecules, like OPG (14). In the present work, we investigated
the mechanisms behind medial calcifications in diabetes, fo-
cusing on one putative factor, i.e., hyperinsulinism. Our data
indicate that insulin at high concentrations may accelerate
calcifications, which may be related to insulin-induced down-
regulation of the presumed calcification inhibitor OPG. How-
ever, it is clear that this scenario cannot explain the whole
picture in the arterial wall in diabetic patients, where increased
and not decreased levels of OPG have been found (14). The
present observations are, nevertheless, important for future
work with calcification models and may provide information
relevant to the mechanisms behind medial calcifications in
diabetes.
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